Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (44)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cercenado, E.
Right arrow Articles by Bouza, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cercenado, E.
Right arrow Articles by Bouza, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 47, 77-81
© 2001 The British Society for Antimicrobial Chemotherapy

Brief report

In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates

Emilia Cercenado*, Fernando García-Garrote and Emilio Bouza

Servicio de Microbiología, Hospital General Universitario ‘Gregorio Marañón’, Dr Esquerdo 46, 28007 Madrid, Spain

The in vitro activity of the oxazolidinone linezolid was compared with the activities of vancomycin and teicoplanin against 450 Gram-positive clinical isolates, including a variety of multiply resistant strains. Linezolid inhibited all microorganisms tested at <=4 mg/L, including methicillin- and teicoplanin-resistant staphylococci, glycopeptide-resistant enterococci, penicillin- and multiply resistant pneumococci and viridans streptococci, and erythromycin-resistant ß-haemolytic streptococci. The MIC90 of linezolid for all isolates was 2 mg/L.

* Corresponding author. Tel: +34-91-586-8459; Fax: +34-91-504-4906; E-mail: fgarrote{at}efd.net


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
K. Credito, G. Lin, and P. C. Appelbaum
Antistaphylococcal Activity of DX-619 Alone and in Combination with Vancomycin, Teicoplanin, and Linezolid Assessed by Time-Kill Synergy Testing
Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1508 - 1511.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. N. Jones, J. E. Ross, T. R. Fritsche, and H. S. Sader
Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations
J. Antimicrob. Chemother., February 1, 2006; 57(2): 279 - 287.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. Lin, K. Smith, L. M. Ednie, and P. C. Appelbaum
Antipneumococcal Activity of Dalbavancin Compared to Other Agents
Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5182 - 5184.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. Bogdanovich, L. M. Ednie, S. Shapiro, and P. C. Appelbaum
Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin
Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4210 - 4219.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. Bogdanovich, D. Esel, L. M. Kelly, B. Bozdogan, K. Credito, G. Lin, K. Smith, L. M. Ednie, D. B. Hoellman, and P. C. Appelbaum
Antistaphylococcal Activity of DX-619, a New Des-F(6)-Quinolone, Compared to Those of Other Agents
Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3325 - 3333.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. Lin, K. Credito, L. M. Ednie, and P. C. Appelbaum
Antistaphylococcal Activity of Dalbavancin, an Experimental Glycopeptide
Antimicrob. Agents Chemother., February 1, 2005; 49(2): 770 - 772.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. M. Ednie, G. Pankuch, and P. C. Appelbaum
Antipneumococcal Activity of LBM415, a New Peptide Diformylase Inhibitor, Compared with Those of Other Agents
Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4027 - 4032.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. Credito, G. Lin, L. M. Ednie, and P. C. Appelbaum
Antistaphylococcal Activity of LBM415, a New Peptide Deformylase Inhibitor, Compared with Those of Other Agents
Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4033 - 4036.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. B. Hoellman, G. A. Pankuch, and P. C. Appelbaum
Antistaphylococcal Activity of CB-181963 (CAB-175), an Experimental Parenteral Cephalosporin
Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4037 - 4039.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
I. Mogenet, S. Raetz-Dillon, J.-M. Canonge, M. Archambaud, and E. Bonnet
Successful Treatment of Staphylococcus epidermidis Hip Prosthesis Infection with Oral Linezolid
Ann. Pharmacother., June 1, 2004; 38(6): 986 - 988.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
A. Van Griethuysen, A. Van 't Veen, A. Buiting, T. Walsh, and J. Kluytmans
High Percentage of Methicillin-Resistant Staphylococcus aureus Isolates with Reduced Susceptibility to Glycopeptides in The Netherlands
J. Clin. Microbiol., June 1, 2003; 41(6): 2487 - 2491.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. F. Smith, M. C. Birmingham, G. A. Noskin, A. K. Meagher, A. Forrest, C. R. Rayner, and J. J. Schentag
Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia
Ann. Onc., May 1, 2003; 14(5): 795 - 801.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. B. Hoellman, G. Lin, L. M. Ednie, A. Rattan, M. R. Jacobs, and P. C. Appelbaum
Antipneumococcal and Antistaphylococcal Activities of Ranbezolid (RBX 7644), a New Oxazolidinone, Compared to Those of Other Agents
Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1148 - 1150.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. C. Moellering Jr.
Linezolid: The First Oxazolidinone Antimicrobial
Ann Intern Med, January 21, 2003; 138(2): 135 - 142.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. Alcala, M. J. Ruiz-Serrano, C. Perez-Fernandez Turegano, D. Garcia de Viedma, M. Diaz-Infantes, M. Marin-Arriaza, and E. Bouza
In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis That Are Susceptible or Resistant to First-Line Antituberculous Drugs
Antimicrob. Agents Chemother., January 1, 2003; 47(1): 416 - 417.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
O. Burkhardt, K. Borner, N. von der Hoh, P. Koppe, M. W. Pletz, C. E. Nord, and H. Lode
Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers
J. Antimicrob. Chemother., November 1, 2002; 50(5): 707 - 712.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Peric, G. Lin, C. L. Clark, M. R. Jacobs, and P. C. Appelbaum
Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents
J. Antimicrob. Chemother., July 1, 2002; 50(1): 95 - 100.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. A. Karlowsky, L. J. Kelly, I. A. Critchley, M. E. Jones, C. Thornsberry, and D. F. Sahm
Determining Linezolid's Baseline In Vitro Activity in Canada Using Gram-Positive Clinical Isolates Collected prior to Its National Release
Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1989 - 1992.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. Pelaez, R. Alonso, C. Perez, L. Alcala, O. Cuevas, and E. Bouza
In Vitro Activity of Linezolid against Clostridium difficile
Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1617 - 1618.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Gander, K. Hayward, and R. Finch
An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model
J. Antimicrob. Chemother., February 1, 2002; 49(2): 301 - 308.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
K. Szczypa, K. Betlejewska, K. Nowak, and K. Hryniewicz
In vitro activity of linezolid against Gram-positive cocci isolated in Poland
J. Antimicrob. Chemother., December 1, 2001; 48(6): 932 - 935.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.